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PARP1 inhibitor (Niraparib, Olaparib, Rucaparib) maintenance therapy improves 
progression-free survival in platinum sensitive sporadic epithelial ovarian cancers. However, 
biomarkers of response to PARPi therapy is yet to be clearly defined. XRCC1, a scaffolding 
protein, interacts with PARP1 during BER and SSBR. In a large clinical cohort of 525 
sporadic ovarian cancers, high XRCC1 or high PARP1 protein levels was not only associated 
with aggressive phenotypes but was also significantly linked with poor progression-free 
survival (p = 0.048 & p=0.001 respectively) and poor ovarian cancer-specific survival (p = 
0.020 & p=0.008 respectively). Pre-clinically, Olaparib and Talazoparib therapy were 
selectively toxic in XRCC1 deficient or knock-out platinum sensitive ovarian cancer cells in 
2D and 3D models. Increased sensitivity was associated with DNA double-strand break 
accumulation, cell cycle arrest and apoptotic cell accumulation. We conclude that XRCC1 
deficiency predicts sensitivity to PARP inhibitor therapy.  PARP1 targeting is a promising 
new approach in XRCC1 deficient ovarian cancers.  
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1. INTRODUCTION  
 
The overall survival for patients with advanced ovarian cancer remains poor despite 
adavances in platinum based chemotherapy. The cytotoxicity of platinum drugs (carboplatin, 
cisplatin) is directly related to induction of intra-strand and inter-strand DNA adducts in cells. 
If unrepaired these DNA damaging lesions can promote the development of DNA double 
strand breaks (DSBs) during replication. Platinum induced DNA damage is detected and 
processed through the DNA repair mechanisms. Development of personalized therapy 
strategy targeting DNA repair is an exciting new strategy in ovarian cancer [1]. The enzyme 
Poly-(ADP)-ribose polymerase 1 (PARP1) is critically involved in DNA repair. PARP1 binds 
to DNA repair intermediates such as single-strand breaks and gets activated which in turn 
leads to the synthesis of PAR (poly-ADP-ribose) polymers. PARP1 auto-PARylation recruits 
other DNA repair factors (including XRCC1) at sites of DNA damage resulting in efficient 
DNA repair [1]. BRCA1 and BRCA2 are critical genes involved in the repair of double 
strand breaks (DSB) through homologous recombination (HR). Women carrying deleterious 
germline mutations in the BRCA1 or BRCA2 genes have a high risk of developing ovarian 
cancers [2]. Synthetic lethality exploits inter-gene relationships where the loss of function of 
either of two related genes is non-lethal, but loss of both causes cell death. This offers the 
potential to specifically target cancer cells through inhibition of a gene known to be in a 
synthetic lethal relationship with a mutated tumour suppressor gene. Synthetic lethality 
approach using PARP inhibitors is an exiciting new strategy in BRCA deficient ovarian 
cancers. PARP inhibitors block PARP1 catalytic activity therby preventing auto-PARylation. 
As a result, base excision repair (BER) recruitment is impaired, PARP1 binding to DNA 
intermediate is stabilised which disrupts replication fork progression leading onto DSB 
accumulation and apoptosis [1].  In BRCA germline deficient or platinum sensitive ovarian 
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cancers, PARP1 inhibitor (Niraparib, Olaparib, Rucaparib) maintenance therapy was recently 
shown to substantially improve progression-free survival in ovarian cancer patients [3-6]. 
However, not all patients respond to PARP inhibitor therapy; either due to intrinsic or 
acqwquired resistance to PARP inhibitors [1, 7]. Therefore the development of alternative  
synthetic lethality targets is urgently needed in epithelial ovarian cancers.    
  
XRCC1 (X-ray repair cross- complementing gene 1) is a scaffolding protein with essential 
roles in DNA repair. The N-terminal domain of XRCC1 binds to DNA strand breaks [8, 9]. 
The central breast cancer gene 1 C-terminal (BRCT I) domain interacts with poly(ADP-
ribose) polymerase 1 (PARP1) , and the additional C-terminal BRCT II domain binds to 
Ligase III  (LIG III) . XRCC1-LIGIII heterodimer is a key player in base excision repair 
(BER) and single strand break repair (SSBR). XRCC1 interacts with PARP1 and also 
coordinates BER/SSBR. XRCC1 also has roles in alternative non-homologous end joining 
(alt-NHEJ) pathway for double strand breaks (DSBs). XRCC1 deficiency delays SSB 
rejoining leading onto SSBs and if unrepaired, eventually to double strand breaks (DSBs) [8, 
9]. In addition, XRCC1 deficiency/mutation can also hyper-activate PARP1 [10]. XRCC1 
deficiency potentiates chemotherapy cytotoxicity [8] including platinum sensitivity in ovarian 
cancer cells [11]. 
 
We hypothesized that XRCC1 could be a promising alternative synthetic lethality target in 
ovarian cancers. In the current study we have comprehensively investigated the expression of 
XRCC1 and PARP1 proteins in a large cohort of 525 human ovarian cancers and have 
confirmed their association with aggressive phenotypes, platinum sensitivity and survival. 
Clinically relevant PARP inhibitors Olaparib and Talazoparib were selectively toxic in 
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XRCC1 deficient ovarian cancer cells. We conclude that XRCC1 deficiency is a predictor of 







2.1. Clinical study 
2.1.1. Patients: Investigation of the expression of XRCC1, PARP1, BRCA1 and BRCA2 
proteins was carried out on tissue microarrays of 525 consecutive ovarian epithelial cancer 
cases treated at Nottingham University Hospitals (NUH) between 1997 and 2010. Patients 
were comprehensively staged as per the International Federation of Obstetricians and 
Gynaecologists (FIGO) Staging System for Ovarian Cancer. Overall Survival was calculated 
from the operation date until the 1st of October 2016 when any remaining survivors were 
censored. Progression-free survival was calculated from the date of the initial surgery to 
disease progression or from the date of the initial surgery to the last date known to be 
progression-free for those censored. Platinum resistance was defined as patients who had 
progression during first-line platinum chemotherapy or relapse within 6 months after 
completion of chemotherapy.  Patient demographics are summarized in Supplementary Table 
S1. None of the tumors were BRCA germ-line deficient.  
2.1.2. Tissue microarray (TMA) and immunohistochemistry (IHC): TMAs were 
constructed as described previously (Kononen et al, 1998). Briefly, triplicate tissue cores 
with a diameter of 0.6mm were taken from the tumour and arrayed into a recipient paraffin 
block using a tissue puncher/arrayer (Beecher Instruments, Silver Spring, MD, USA) as 
previously described (Kononen et al, 1998). Four micron sections of the tissue array block 
were cut and placed on Surgipath X-tra Adhesive microscope slides (Leica Microsystems) for 
immunohistochemical staining. Immunohistochemical staining was performed using 
Novocastra Novolink polymer detection system according to manufacturer instructions 
(Leica Microsystems, Newcastle, UK). Pre-treatment of TMA sections was performed with 
citrate buffer (pH 6.0, 20 min, Microwave). A set of TMA sections were incubated for 30 min 
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at room temperature with 1:250 anti-XRCC1 mouse monoclonal antibody (Ab-1, clone 33-2-
5, Thermoscientific, Fremont, CA). A set of TMA sections were stained with mouse anti-
human PARP1 antibody (clone 46D11, Cell signalling, USA) (1:600) for 60 min incubation 
in room temperature. A set of TMA sections were stained with anti-BRCA1 (Merck 
Millipore, UK) (1:200) and further set were stained with anti-BRCA2 (Abcam, UK) (1:100), 
both were incubated for 1h at room temperature. Sections were counterstained with 
haematoxylin. Negative controls with no primary antibody were included in each run. Cases 
with multiple cores were scored and the average was used as the final score.  
2.1.3. Evaluation of immune staining: Whole field inspection of the core was scored, and 
the subcellular localisation of each marker was identified (nuclear, cytoplasm, cell 
membrane). Intensities of subcellular compartments were each assessed and grouped as 
follows: 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining. The 
percentage of tumour cells in each category was estimated (0–100%). H-score (range 0–300) 
was calculated by multiplying the intensity and the percentage of staining. For XRCC1, 
Low/negative nuclear level was defined by median of H-score of ≤ 100. H score of <80 
nuclear PARP1 staining was considered as low/negative which was identified by the median. 
For BRCA1 nuclear H-score <80 was considered low/negative. While, H-score < 120 were 
considered low/ negative for nuclear BRCA2 expression. Both BRCA1/BRCA2 cut off points 
were identified by X-tile.  Not all cores within the TMA were suitable for IHC analysis due to 
missing cores or absence of tumour cells. 
2.1.4. Statistical analysis: This was performed using SPSS v 22 (Chicago, IL, USA) for 
Windows. Association with clinical and pathological parameters using categorised data was 
examined using Chi-squared test. All tests were 2-tailed. Survival rates were determined 
using Kaplan–Meier method and compared by the log-rank test. All analyses were conducted 
using Statistical Package for the Social Sciences (SPSS, version 22, Chicago, IL, USA) 
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software for windows. P value of less than 0.05 was identified as statistically significant. This 
work was approved by the Nottingham Research Ethics Committee. 
 
2.2. Pre-clinical study 
2.2.1. Compounds and reagents: Olaparib (AZD2281) was kindly provided by AstraZeneca 
Pharmaceuticals. Talazoparib and PDD00017273 was purchased from (Selleckchem, UK). 
The antibodies used in the current study are as follows; XRCC1 antibody clone (33-2-5) 
(Thermofisher, UK), histone H2AX phosphorylated at Ser139 (γH2AX; 05–636; Millipore, 
UK) and PARP1 antibody (Cell signalling, USA). Pre-validated XRCC1 siRNA was 
purchased from Invitrogen. Lipofecamine3000 reagent, Calcein AM and Ethidium 
homodimer -1 all were purchased from Thermofisher, UK.  
2.2.2. Cell lines and culture: A2780 (platinum sensitive), A2780cis (platinum resistant) and 
OVCAR3 , OVCAR4, PE04 and SKOV3 cell lines were purchased from American Type 
Culture Collection (ATCC, Manassas, USA) [12].Cells were cultured in RPMI medium 
supplemented with 10%FBS and 1% penicillin streptomycin. To maintain cisplatin resistance 
in A2780cis, cells were exposed to 1μM cisplatin every 2-3 passages. 
2.2.3. Targeted next generation sequencing: Genomic DNA was extracted from cell lines 
using the PicoPure™ DNA Extraction Kit (Thermofisher,UK) . Targeted next-
generation sequencing was used to identify genomic variants in A2780 and A2780cis. 
Library preparation and sequencing was conducted by Source Biosciences (Nottingham, UK). 
2.2.4. Transient SiRNA transfection: Cells were seeded at 60-70% confluency in t25 flasks 
overnight, XRCC1 siRNA were delivered to the cells in opti-mem using Lipofecamine 3000 
reagent (Invitrogen, UK) as per the manufacturer’s protocol. Cell lysates were collected in 
RIPA buffer (Sigma, UK) supplemented with phosphatase inhibitor cocktail and protease 
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inhibitors cocktails (Sigma,UK). The efficiency of transfection was confirmed using western 
blotting. 
2.2.5. CRISPR Knock-out of XRCC1: A2780 cells were transfected with oligonucleotides 
carrying gRNA silencing XRCC1cloned in a Plv-U6g-EPCG plasmid (Sigma, UK).Briefly, 
cells were seeded at 50- 60 % confluency in 6 well plates overnight. Cells were transfected 
with 2-3 µg of DNA using Lipofectamine 3000(Invitrogen, UK) in an Opti-MEM medium. 
After 48 hours Puromycin selection started for stable clones. A2780 cells were selected in 
5μg/ml puromycin for 14 days. The efficiency of XRCC1_KO was confirmed using western 
blot analysis. Multiple clones were selected and  used in the current study. 
2.2.6. Clonogenic assays: 250 cells were seeded in 6- well plates overnight. Olaparib and 
talazoparib and PDD00017273 were added at the indicated concentrations. The plates were 
left in the incubator for 14 days, after incubation colonies were washed with PBS, fixed and 
stained with crystal violet, acetic acid and methanol mixture and counted. 
2.2.7. Cell Proliferation assays: 100 cells /well were seeded in 96-well plates, Left to adhere 
overnight. Olaparib, talazoparib and PDD00017273 were tested at the indicated 
concentrations. After 5 days cell viability was measured by cell titer cell proliferation assay 
(MTS) (Promega, UK). 
2.2.8. Cell cycle analysis: Cells were seeded in 6- well plates overnight then treated with 
10μM of Olaparib or 5 μM of talazoparib or 10 μM of PDD00017273 for 24 hours. Cells 
were collected by trypsinization and washed with ice cold PBS, then fixed in 70% ethanol for 
30 mins. Ethanol was washed away and the cells were then treated with RNase 5µg/ml and 
stained with 10ug/ml propidium iodide (Sigma Aldrich).  
2.2.9. Detection of DSBs by γH2AX staining: Cells were seeded in 6- well plates overnight 
then treated with 10μM of Olaparib or 5 μM of talazoparib or 10 μM of PDD00017273 for 24 
hours. Cells were collected by trypsinization and washed with ice cold PBS, then fixed in 
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70% ethanol for 30 mins. Ethanol was washed away and the cells were stained with phospho 
Histone (γH2AX) Ser139 FITC antibody.  
2.2.10. Annexin-V assay for apoptosis: Cells were seeded in 6- well plates overnight then 
treated with 10μM of Olaparib or 5 μM of Talazoparib 10 μM of PDD00017273 for 24 hours. 
Cells were collected by trypsinization, washed with ice cold PBS, stained with AnnexinV 
detection kit (BD biosciences) and analysed by Flow cytometry. 
Confocal microscopy: Cells were seeded on the cover slips overnight, then treated with 
PDP00017273 for the indicated time-points. The cells were fixed with 4% (w/v) 
paraformaldehyde for 30 min, permeabilized with 0.1% (w/v) Triton X100 (ThermoFisher) 
for 30 min and blocked with 3% (w/v) BSA for 1 h. Cells were incubated with anti-
Poly(ADP-Ribose) polymer antibody (Abcam, ab14459) or with anti- 53BP1 (Cell 
Signalling, catalogue no. 4937S) and anti γH2AX (Merck millipore clone JBW301)  
overnight at 4°C. Slides were prepared in duplicates. Imaging was carried out using Leica 
SP2 confocal laser scanning microscope. For analysis a minimum of 100 cells per slide were 
counted. 
 
2.2.11. Invasion and migration assays: A2780 (control) and A2780 (XRCC1_KO) were 
seeded in the Upper chamber of polycarbonate membrane inserts (8 µm pore size), (Cell 
biolabs,UK)  in serum free medium and left to migrate toward 10% serum containing 
medium for 24 hours. After 24 hours medium containing non- invasive cells were aspirated 
from the inserts and the inner was washed with distilled water then stained with crystal violet 
for 10 minutes. Cells were extracted and 100 µL from each sample were transferred to 96-
well microtiter plate for measuring OD at 560nm. For migration assays, cells were seeded in 
96 well plate containing hydrogel spot non migratory area, left to adhere overnight and then 
the hydrogel area was digested and cells were left to migrate for 20 hours. Then the wells 
12 
 
were washed three times, fixed and stained as per manufacturer protocol. Cell migration 
images were analysed by Imagej software. 
2.2.12. Generation of 3D spheroids: A2780 control & XRCC1_ KO were seeded in ultra-
low attachment 6-well plates using the promo cell tumour spheres medium. After 14 days, 
cells were treated with the indicated concentrations of Olaparib, Talazoparib or 
PDD00017273. Then cells were fixed with formaldehyde 3.7% and stained with 2µM calcein 
AM and 1.5µM ethidium homodimer-1. Imaging was carried out using Leica SP2 confocal 
laser scanning microscope. Quantification of live/dead staining was carried out by flow 
cytometry. 
2.2.13. Statistical analysis:  Statistical data are presented as mean ± SD of at least three 
independent biological experiments. P values were calculated with either the Student two-
tailed t test and one way ANNOVA for normally distributed datasets or the nonparametric 








3.1. XRCC1 expression in ovarian cancers: A total of 442 tumours were suitable for 
analysis of XRCC1 nuclear expression (Figure 1A) as not all cores within the TMA were 
suitable for IHC analysis due to missing cores or absence of tumour cells.  147/442 (33.3%) 
tumours were low for XRCC1 expression, and 295/442 (66.7%) of the tumours were high in 
expression (Supplementary Table S2). High expression was significantly associated with 
serous cystadenocarcinomas (p <0.0001) and higher FIGO stage at presentation (p = 0.001). 
In addition, tomour with high XRCC1 expression were likely to have measurable disease 
before chemotherapy (p= 0.002) indicating sub-optimal debulking at surgery. Platinum 
resistance was defined as patients who had progression during first-line platinum 
chemotherapy or relapse within 6 months after completion of chemotherapy. Patients with 
tumours with high XRCC1 expression were significantly more likely to be resistant to 
platinum treatment (p = 0.003) (Supplementary Table 2).  High XRCC1 expression in 
tumours showed an adverse clinical outcome with progression-free survival (PFS) (p = 0.048) 
(Figure 1B) and poor ovarian cancer-specific survival (OCSS) (p = 0.020) (Figure 1E) 
compared with tumours that had low XRCC1 expression.  Together the data provides clinical 
evidence that high XRCC1 is a feature of aggressive ovarian cancers and predicts platinum 
resistance and poor survival in patients. 
 
3.2. PARP1 expression in ovarian cancers: A total of 301 tumours were suitable for 
analysis of PARP1 nuclear expression (Figure 1A) as not all cores within the TMA were 
suitable for IHC analysis due to missing cores or absence of tumour cells.  208/401 (51.9%) 
tumours were high for PARP1 expression and 193/401 (48.1%) of the tumours were low in 
expression. High expression was significantly associated with serous cystadenocarcinomas 
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(p <0.00001), higher grade (p = <0.00001), and measurable disease before chemotherapy (p= 
0.024) compared with low expression tumours (Supplementary Table 3). High PARP1 
expression in tumours showed adverse clinical outcome with poor PFS (p = 0.001) 
(Figure1C) and poor OCSS (p = 0.008) (Figure1F) compared with tumours that had low 
PARP1 expression. The data suggests that high PARP1 expression has predictive and 
prognostic significance in ovarian cancers. 
 
3.3. XRCC1/PARP1 co-expression and ovarian cancers: We then conducted 
PARP1/XRCC1 co-expression analysis. Tumours with high expression of both PARP1 and 
XRCC1 showed significant correlation with serous cystadenocarcinoma subtype (p <0.0001), 
high grade of malignancy (p=0.002) and residual disease before the initiation of 
chemotherapy (p=0.004) (Supplementary Table S4). Tumours that have low PARP1/XRCC1 
protein expression have non-significant improvement in PFS (p=0.090) (Figure 1D) and 
favourable OCSS (p = 0.010) (Figure 1G). 
 
3.4. Multivariate analysis: In cox multivariate model, platinum sensitivity (p<0.001) and 
XRCC1 (p=0.016) were independently associated with PFS. For OCSS, platinum sensitivity 
(p<0.001) and PARP1 (p=0.023) were independently linked with survival (Supplementary 
Table S5). 
 
Taken together the clinical data provides evidence that XRCC1 deficiency is associated with 
platinum sensitivity. PARP targeting could be promising approach in XRCC1 deficient 





3.5. XRCC1 deficiency and PARP inhibitor sensitivity in ovarian cancer cells: PARP1 
inhibitors (Olaparib, Niraparib and Rucaparib) are standard maintenance therapies to prolong 
PFS in platinum sensitive sporadic ovarian cancers. Previously, we shown that low XRCC1 
level was linked to platinum sensitivity in ovarian cancers [11].  XRCC1 deficient ovarian 
cancer cell lines were also sensitive to platinum treatment in that study [11]. We therefore 
tested the hypothesis that PARP inhibitor therapy could be synthetically lethal in XRCC1 
deficient ovarian cancer cells.   
A2780 is a well described platinum sensitive ovarian cancer cell line established from a 
patient with previously untreated ovarian cancer and A2780cis is a platinum resistant cell line 
developed by chronic exposure of the parent cisplatin-sensitive A2780 cell line to increasing 
concentrations of cisplatin [12]. In targeted deep sequencing we did not identify any mutations 
in BRCA1 or BRCA2 genes. In clonogenic assay, we first confirmed platinum sensitivity or 
resistance in A2780 and A2780cis cells respectively (Figure 2A). We then depleted XRCC1 
using siRNAs in A2780 and A2780cis cells (Figure 2B). XRCC1 deficiency leads to single 
strand break (SSB) accumulation which gets converted to double strand breaks (DSBs) in cells. 
XRCC1 deficiency has previously been shown to activate PARP1[10]. In XRCC1 deficient 
ovarian cancer cells, we observed  increased PARP1 protein levels compared to control cells 
(Figure 2C). Olaparib (PARP inhibitor) was significantly cytotoxic in XRCC1 deficient A2780 
cells compared to control A2780 cells (Figure 2D). Increased cytotoxicity was associated with 
significant accumulation of γH2AX (Figure 2E), G2M cell cycle arrest (Figure 2F) and 
increased apoptosis (Figure 2G). In A2780cis XRCC1 deficient cells, although, Olaparib 
modestly increased γH2AX (Figure 2E), G2M cell cycle arrest (Figure 2F) and increased 
apoptotic cells (Figure 2G) Olaparib did not significantly increase cytotoxicity as assessed by 
clonogenic assays (Figure 2D). The data therefore suggests preferential cytotoxicity of Olaparib 
in XRCC1 deficient platinum sensitive A2780 ovarian cancer cells. To confirm this observation 
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further we tested a panel of additional ovarian cancer cell lines; OVCAR3, OVCAR4, PEO4 
and SKVO3 [12]. XRCC1 depletion in OVCAR3, OVCAR4, PEO4 and SKVO3 cells 
increased sensitive to Olaparib therapy compared to control cells (Figure 2H, 2I, 2J, 2K). 
To validate further, we generated XRCC1 knock-out (KO) in A2780 cell line using 
CRISPR/cas-9 methodology (Figure 3A). A2780 (XRCC1_KO) cells were similarly sensitive 
to Olaparib treatment (Figure 3A). We speculated that the increased toxicity observed in 
XRCC1 deficient cells may be due to not only PARP inhibition but also due to the ability of 
Olaparib to "trap" PARP proteins thereby leading to SSB and DSB accumulation. To test this 
hypothesis, we evaluated another clinically relevant PARP inhibitor Talazoparib which is at 
least 100 times more potent than Olaparib for PARP trapping. As shown in (Figure 3C), 
XRCC1_KO cells were hypersensitive to Talazoparib therapy. We further confirmed 
Talazoparib sensitivity in additional ovarian cancer cell lines. XRCC1 depleted OVCAR4, 
PE04 and SKOV3 cells were extremely sensitive to Talazoparib treatement (Supplementary 
Figure S2A, S2B, S2C). Olaparib and Talazoparib sensitivity in A2780(XRCC1_KO) cells 
were associated with increased DNA damage as evident by increased H2AX nuclear foci 
(Figure 2D &2E), 53BP1 foci accumulation (Figure 2D& 2F). We further validated DSBs 
accumulation by H2AX flow cytometry staining. As expected, Olaparib treatment in A2780 
(XRCC1_KO) cells leads to H2AX accumulation (Figure 4A), G2M cell cycle arrest (Figure 
4B) and increased apoptosis (Figure 4C). Talazoparib treatment A2780 (XRCC1_KO) cells 
was associated with substantial H2AX accumulation (Figure 4D), G2M cell cycle arrest 
(Figure 4E) and high levels of apoptosis (Figure 4F). 
At sites of DNA damage, PARP1 is recruited where it induces the synthesis of poly (ADP-
ribose) (PAR). PARylation of PARP1 and other DNA repair factors is essential for 
coordination of DNA repair. PARylation is transient and reversible. 
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PAR glycohydrolase (PARG) is a key factor in the PAR degradation pathway [13-15]. PAR 
is degraded by PARG through its endo- and exoglycosidase activities. Recently, PARG has 
emerged as a promising drug target in cancer. The specific PARG inhibitor PDD00017273 
was shown to induce synthetic lethality in BRCA1, BRCA2, PALB2, FAM175A 
(ABRAXAS) and BARD1 deficient breast cancer cells [16, 17]. We therefore tested cellular 
activity of PDD00017273 in XRCC1 deficient ovarian cancer cells. As shown in Figure 5A, 
5B, 5C and 5D, we did not observe any increased sensitivity to PDD00017273 in XRCC1 
deficient ovarian cancer cells. 
3.6. 3D spheroid studies: To recapitulate in vivo system, we generated 3D-spheroids of 
A2780 control and A2780_ XRCC1 KO cells. Similar to control cells, untreated XRCC1 KO 
cells retain spheroid forming capacity (Figure 5E). However, upon Olaparib treatment, in 
XRCC1 KO spheroids, there was not only reduction in spheroid size (Figure 5E) but also 
accumulation of apoptotic cells (Figure 5G) compared to control spheroids (Figure 5E & 5F). 
Interestingly, Talazoparib therapy induced a striking reduction in spheroid size (Figure 5E) 
and viability in XRCC1 KO cells compared to control cells (Figure 5E & 5G). However, 
PDD00017273 (PARGi) did not affect spheroid size or induce cell death (Figure 5E & 5G).  
Together, the data provides further evidence that XRCC1 deficient cells are sensitive to 
PARP inhibitors but not to PARG inhibition in ovarian cancer cells.  
 
Given the  potential role for DNA repair in migration and invasion [18, 19], we also tested 
XRCC1 proficient and XRCC1_KO cells in mgration and invasion assays. As shown in Figure 
6A and 6B, compared to control cells, XRCC1_KO_A2780 cells were less migratory and 




3.7. BRCA and XRCC1 co-expression in ovarian cancers: To evaluate the 
clinicopathological significance of BRCA1 or BRCA2 protein expression in sporadic ovarian 
cancers, we completed BRCA1 and BRCA2 staining by immunohistochemistry in the ovarian 
cancer cohort (Supplementary Figure S2D).  We then proceeded to XRCC1/BRCA co-
expression analyses. The full data is shown in Figure 6C & 6D, Supplementary Figures S3 & 
S4 and Supplementary Tables S6, S7, S8 & S9.  As shown in supplementary Figure S3, in 
BRCA1 low expressing tumours,  high XRCC1 was associated with poor PFS (borderline 
non-significant, p=0.061) (Supplementary Figure S3A) and OS (p=0.025) (Supplementary 
Figure S3B). Similarly, in BRCA2 high tumours, high XRCC1 expression was associated 
with poor PFS (p=0.003) (Supplementary Figure S3G) and OS (p=0.003) (Supplementary 
Figure S3H). Additionally, high BRCA2/XRCC1 co-expression was significantly associated 
with poor PFS (p= 0.016) (Figure 6C) and OS (p= 0.010) (Figure 6D). Similarly, high 
BRCA1/XRCC1 co-expression remained associated with PFS (p= 0.063) (Supplementary 
Figure S4A) and OS (P= 0.006) (Supplementary Figure S4B). Together the data suggests that 




The scaffolding protein XRCC1 is a key player in BER, SSBR, and alt-NHEJ. XRCC1 
deficiency delays SSB rejoining induces mutations and results in elevated levels of sister 
chromatid exchanges [8, 9]. In addition, XRCC1 deficiency or mutation can also hyper-
activate PARP1 [10]. XRCC1 depletion increases ionizing radiation and chemotherapy 
sensitivity in cells [8, 9]. Genetic polymorphisms in XRCC1 may influence cancer risk and 
response to platinum based chemotherapy in patients [20-23]. In ovarian cancer patients 
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XRCC1 Arg399Gln and XRCC1 Arg194Trp polymorphism may influence clinical outcome 
[22].    
 
In a previous preliminary study of 195 sporadic ovarian cancer patients treated at Nottingham 
University Hospitals (NUH) between 2000 and 2007, we have shown that XRCC1 
overexpression was linked to platinum resistance and poor PFS [11]. We have since 
expanded this cohort to include a further 330 patients with sporadic ovarian cancer treated 
from 2007 to 2010. In this large cohort of 525 ovarian tumours, we not only confirmed our 
previous observation but have also evaluated the expression of PARP1, BRCA1 and BRCA2 
proteins.  In addition, we have shown that PARP1 overexpression also impacted negatively 
on PFS and OCSS. The data would concur with previous studies also showing predictive 
significance of PARP1 in ovarian cancers[24, 25]. As PARP1 and XRCC1 interact with each 
other during BER [26], we also performed co-expression analyses in ovarian cancer cohorts. 
We demonstrate that patients with tumours that have low PARP1 and low XRCC1 expression 
have better PFS and OCSS.  
 
Ovarian cancer patients with germ-line mutations in BRCA1 and BRCA2 have been shown 
to clinically benefit from PARP inhibitor therapy [3-6]. However, biomarkers of response in 
sporadic tumours are an area of intense investigation [27]. Homologous recombination repair 
(HRR) deficiency assays (such as targeted multiplex sequencing, genomic scars, functional 
assays) and altered DNA repair gene and/or protein expression in tumours are promising 
approaches to personalize PARP inhibitor therapy in ovarian cancers [27]. Previously we 
have shown that XRCC1 deficient ovarian cancer cells are sensitive to platinum treatment 
[11]. A previous synthetic lethality screening study using a large siRNA library identified 
XRCC1 as a potential synthetic lethality partner for PARP inhibition [28].  In the current 
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study, we provide confirmatory pre-clinical evidence that XRCC1 deficient ovarian cancer 
cell lines are hypersensitive to PARP inhibitor therapy through synthetic lethality. A model 
for synthetic lethality has been suggested previously [29] and summarized as follows; PARP1 
binds to sites of single strand breaks. Activation of PARP1 leads to the synthesis of PAR 
(poly-ADP-ribose) polymers. Auto-PARylation of PARP1 and PARylation of other proteins 
recruits XRCC1 (and other BER factors) to sites of DNA damage promoting DNA repair. 
Inhibition of PARP1 catalytic activity (by Olaparib, Talazoparib) prevents auto-PARylation, 
impairs BER recruitment and stabilises binding of PARP1 to DNA intermediate. DNA-bound 
immobilised PARP-1 disrupts replication fork progression, leads to double-strand break 
(DSB) accumulation and DSB-mediated apoptosis. In XRCC1 deficient cells with increased 
SSB accumulation, PARP inhibition mediated accumulation of DSB is more pronounced 
compared to XRCC1 proficient cells thereby leading to synthetic lethality. Accordingly in 
XRCC1 deficient ovarian cancer cells, Olaparib or Talazoparib therapy lead to DSB 
accumulation, cell cycle arrest and induced apoptosis. Although our data suggests that 
XRCC1 deficient ovarian cancer cells are more sensitive to Talazoparib compared to 
Olaparib,  it is important to recognise that Talozoparib is a much more potent PARP inhibitor 
and the concentration of Talozoparib (5μM) is substantially more cytotoxic than the 
concentration of Olaparib (10 μM) used in our study. Moreover, further in vivo studies will 
also be required to evaluate the clinical potential of this approach in XRCC1 deficient ovarian 
cancers. In XRCC1 deficient breast cancer models, we have recently confirmed PARP 
inhibitor sensitivity compared to XRCC1 proficient breast cancer cells [30]. Taken together, 
the data presented provides strong evidence for a new synthetic lethality strategy in XRCC1 




Hoch et al demonstrated that XRCC1 knockdown increased PARP1 activity [10]. An 
interesting observation in the current study was that we also observed an increase in the 
expression of PARP1 in XRCC1 deficient cells. In a recent study in breast cancers, we 
similarly showed that XRCC1 deficient breast cancer cells also have increased PARP1 
expression compared to wild type cells [30]. We speculate that increased PARP1 level may 
also contribute to a hyperactive PARP1 status seen in XRCC1 deficient cells which 
accumulate single strand breaks. Interestingly, emerging evidence suggests that PARP1 may 
be subjected to transcriptional regulation such as through Sp-1 transcription factor [31]. 
Whether such a mechanism operates in XRCC1 deficient cells is unknown but will be an 
interesting area for future investigation.   
 
In previous studies in melanoma [18] and clear cell renal cancer cells [19], XRCC1 depletion 
was shown to promote invasion. In addition, we have recently shown that XRCC1 depletion 
in breast cancer DCIS cells promote invasion [30]. We therefore explored the role of XRCC1 
in ovarian cancer cells. Interestingly, XRCC1 depletion resulted in reduction in invasion and 
migration in A2780 cells. Taken together, the data would imply differential roles of XRCC1 
in influencing invasion or migration indifferent tumour types.  
 
A recent study suggested that XRCC1 deficient cells may also be sensitive to PARG inhibitor 
treatment [32]. PARG inhibition was shown to increase PAR level and deplete of cellular 
NAD in that study [32]. However, we did not observe increased sensitivity in PARG inhibitor 
(PDD00017273) treated XRCC1 deficient ovarian cancer cells. The data would imply that 
PARG inhibitor sensitivity could be cell line dependent. In a recent study by Pillay et al, 
differential sensitivity to PARG inhibitor (PDD00017273) and PARP inhibitor (Olaparib) 
was demonstrated in a panel of ovarian cancer cell lines [33]. The authors showed that 
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PARGi sensitivity in certain ovarian cancer cell lines was due to replication vulnerabilities 
that render cells dependent of PARG activity for survival. PARG inhibiton in this context 
induced synthetic lethality [33]. On the other hand, synthetic lethality due to PARP inhibitors 
is related to impaired DNA repair capcity such due to BRCA deficiency [1] or due to XRCC1 
deficiency shown in the current study.   
 
In conclusion, we provide clinical and pre-clinical evidence that XRCC1 deficient ovarian 
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Figure 1: Prognostic and predictive significance of XRCC1 and PARP1 expression in 
ovarian cancers. (A) Representative photomicrographic images of XRCC1 and PARP1 
immunohistochemical expression in ovarian tissue microarrays. (B) Kaplan Meier curves for 
XRCC1 protein expression showing progression free survival (PFS). (C) Kaplan Meier 
curves for PARP1 protein expression showing progression free survival (PFS). (D) Kaplan 
Meier curves for XRCC1-PARP1 co-expression showing progression free survival (PFS). (E) 
Kaplan Meier curves for XRCC1 showing overall survival (OCSS). (F) Kaplan Meier curves 
for PARP1 showing OCSS. (G) Kaplan Meier curves for XRCC1-PARP1 co-expression 
showing OCSS. 
 
Figure 2: XRCC1 deficiency and Olaparib induced synthetic lethality. (A) Clonogenic 
survival assay for cisplatin sensitivity in A2780 and A2780cis cells. (B) Western blot of 
XRCC1 levels in A2780 and A2780cis transfected with XRCC1 siRNA or scrambled siRNA 
control. (C) Western blot of PARP1 and quantification in A2780, A2780cis control and 
XRCC1 knock down. (D) Clonogenic survival assay for A2780, A2780cis control and 
XRCC1 knock down treated with different doses of Olaparib. Cells were plated overnight and 
then transfected with XRCC1 siRNA or scrambled siRNA control. On day two, cells were 
trypsinized, collected and re-plated in 6-well plates for clonogenic assays. On day three, cells 
were treated with indicated doses of Olaparib. For Flow cytometry analysis, transfected cells 
were plated on day two overnight and then treated with 10μM of Olaparib for 24 hrs. (E) 
Quantification of γH2AX levels by flow cytometry in untreated (UT) or Olaparib treated                                                                                            
(10µM) control and XRCC1_KD cells. (F) Quantification of cell cycle progression by flow 
cytometry in untreated (UT) or Olaparib treated (10µM)  control and XRCC1_KD cells. (G) 
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Quantification of apoptotic cells by Annexin V flow cytometry in untreated (UT) or Olaparib 
treated (10µM) cells control and XRCC1_KD cells. (H) Clonogenic survival assay for 
OVCAR3 scrambled control and OVCAR3(XRCC1_KD) cells in different doses of Olaparib. 
(I) Clonogenic survival assay for OVCAR4 scrambled control and OVCAR4(XRCC1_KD) 
cells in different doses of Olaparib. (J) Clonogenic survival assay for PE04 scrambled control 
and PE04 (XRCC1_KD) cells in different doses of Olaparib. (K) Clonogenic survival assay 
for SKOV3 scrambled control and SKOV3(XRCC1_KD) cells in different doses of Olaparib. 
All figures are representative of 3 or more independent experiments. P values are indicated as 
follows; ‘*’ p<0.05, ‘**’ p<0.01, ‘***’ p<0.001. Error bar indicates standard error of mean. 
 
Figure 3: PARP1 inhibitor sensitivity in A2780 XRCC1 knock out cells. (A) Western blot 
showing XRCC1koock out in A2780 using CRISPR-Cas9 methodology. (B) Clonogenic 
survival assay for A2780 control and A2780 XRCC1_KO cells in different doses of Olaparib. 
(C) Clonogenic survival assay for A2780 control and A2780 XRCC1_KO cells in different 
doses of Talazoparib. (D) Representative photomicrographic images of 53BP1 and H2AX 
immunofluorescence staining in A2780 cantrol and XRCC1_KO cells treated with Olaparib 
(10M) or Talazoparib (5M) for 24 h. (E) Quantification of 53BP1 and H2AX mean 
fluorescence intensity by ImageJ software. For analysis minimum of 100 cells were counted. 
All figures are representative of 3 or more independent experiments. P values are indicated as 
follows; ‘*’ p<0.05, ‘**’ p<0.01, ‘***’ p<0.001. Error bar indicates standard error of mean. 
 
Figure 4: Functional studies of PARP1 inhibitor induced synthetic lethality in A2780 
XRCC1_KO cells. (A) Quantification of γH2AX levels by flow cytometry in untreated (UT) 
or Olaparib treated (10µM) A2780 control and XRCC1_KO cells. (B) Quantification of cell 
cycle progression by flow cytometry in untreated (UT) or Olaparib treated (10µM) A2780 
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control and XRCC1_KO cells. (C) Quantification of apoptotic cells by Annexin V flow 
cytometry in untreated (UT) or Olaparib treated (10µM) A2780 control and XRCC1_KO 
cells. (D) Quantification of γH2AX levels by flow cytometry in untreated (UT) or 
Talazoparib treated (5 µM) A2780 control and XRCC1_KO cells. (E) Quantification of cell 
cycle progression by flow cytometry in untreated (UT) or Talazoparib treated (5µM) A2780 
control and XRCC1_KO cells. (F) Quantification of apoptotic cells by Annexin V flow 
cytometry in untreated (UT) or Talazoparib treated (5µM) A2780 control and XRCC1_KO 
cells. 
 
Figure 5: PARP1 inhibitor or PARG inhibitor sensitivity in XRCC1 Knockout (KO) cells. 
(A) Clonogenic survival assay of A2780 control and XRCC1 knock out treated with the 
indicated doses of PDD00017273. (B) Quantification of γH2AX levels by flow cytometry in 
untreated (UT) or PDD00017273 treated (10 µM) A2780 control and XRCC1_KO cells. (C) 
Quantification of cell cycle progression by flow cytometry in untreated (UT) or 
PDD00017273 treated (10 µM) A2780 control and XRCC1_KO cells. (D) Quantification of 
apoptotic cells by Annexin V flow cytometry in untreated (UT) or PDD00017273 treated (10 
µM) A2780 control and XRCC1_KO cells . (E) Representative photomicrographic images of 
A2780 control and XRCC1_KO 3D spheres treated with Olaparib (10µM), Talazoparib 
(5µM), and PDD00017273 (10µM). Quantification of viable, dead cells by flow cytometry 
in: A2780control (F) and A2780 (XRCC1_KO) (G) treated with Olaparib, Talazoparib and 
PD00017273. See methods for further details. All figures are representative of 3 or more 
independent experiments. P values are indicated as follows; ‘*’ p<0.05, ‘**’ p<0.01, ‘***’ 




Figure 6: (A) Representative images for migration assay in A2780 control and 
A2780(XRCC1_KO) cells. CytochalasinD (1.5M) was used as a negative control. 
Quantification was performed in ImageJ software. (B) Representative images for invasion 
assay and quantification in A2780 control and A2780 (XRCC1_KO) cells.  P values are 
indicated as follows; ‘*’ p<0.05, ‘**’ p<0.01, ‘***’ p<0.001. Error bar indicates standard 
error of mean. (C) Kaplan Meier curves for BRCA2-XRCC1 co-expression showing PFS. 













Supplementary Figure S1: (A)Representative images for cell H2AX analysis by flow
cytometry, (B) Representative images for cell cycle analysis by flow cytometry & (C)
Representative images for annexinV analysis by flow cytometry in A2780 and A2780cis
control and XRCC1_KD cells untreated and treated with Olaparib (10.M).
Supplementary Figure S2: (A) Clonogenic survival assay for OVCAR4 scrambled control
and OVCAR4(XRCC1_KD) cells treated with the indicated doses of Talazoparib. (B)
Clonogenic survival assay for PEO4 scrambled control and PEO4(XRCC1_KD) cells treated
with the indicated doses of Talazoparib. (C) Clonogenic survival assay for SKOV3 scrambled
control and SKOV3(XRCC1_KD) cells treated with the indicated doses of Talazoparib. (D)
Representative photomicrographic images for BRCA1/BRCA2 immunohistochemical
staining in ovarian tissue microarrays.
Supplementary Figure S3: (A) Kaplan Meier curve for XRCC1 protein expression and PFS
in ovarian cancers in BRCA1 low tumours. (B) Kaplan Meier curve for XRCC1 protein
expression and OS in BRCA1 low ovarian cancers. (C) Kaplan Meier curve for XRCC1
protein expression and PFS in BRCA1 high ovarian cancers. (D) Kaplan Meier curve for
XRCC1 expression and OS in BRCA1 high ovarian cancers. (E) Kaplan Meier curve for
XRCC1 expression and PFS in BRCA2 low ovarian cancers. (F) Kaplan Meier curve for
XRCC1 expression and OS in BRCA2 low ovarian cancers. (G) Kaplan Meier curve for
XRCC1 expression and PFS in BRCA2 high ovarian cancers. (H) Kaplan Meier curve for
XRCC1 expression and OS in BRCA2 high ovarian cancers.
Supplementary Figure S4: (A) Kaplan Meier curves for BRCA1-XRCC1 co-expression
showing PFS. (B) Kaplan Meier curves for BRCA1-XRCC1 co-expression showing OS.
Supplementary Table S1: Patient demographics
Number PercentagesCharacteristics
Pathology
Serous cystadenocarcinoma 290 55.2%
Endometrioid 82 15.6%
Clear cell carcinoma 48 9.1%























Carboplatin monotherapy 163 31%
Carboplatin + Paclitaxel 177 34%
Other platinum based regimes* 121 23%














Supplementary Table S2: Clinicopathological significance of XRCC1 expression in
Ovarian Cancers.
FIGO= International Federation of Obstetricians and Gynaecologists (FIGO) Staging System
for Ovarian Cancer
G= tumour grade
* = Platinum resistance was defined as patients who had progression during first-line
platinum chemotherapy or relapse within 6 months after completion of chemotherapy
XRCC1- N(%) XRCC1+ N(%)
P- value
Pathological Type <0.00001
Serous cystadenocarcinoma 66 (24.7) 201 (75.3)
Mucinous
cystadenocarcinoma
23 (47.9) 25 (52.1)
Endometrioid 30 (41.7) 42 (58.3)
Clear cell carcinoma 24 (58.5) 17 (41.5)
Mixed 4 (28.6) 10 (71.4)
FIGO Stage 0.001
I 70 (44.9) 86 (55.1)
II 18 (26.5) 50 (73.5)
III 58 (29.7) 137 (70.3)
IV 5 (16.7) 25 (83.3)
Tumour Grade 0.105
G1 27 (46.6) 31 (53.4)
G2 24 (31.6) 52 (68.4)




No measurable disease 111 (39.6) 169 (60.4)
Measurable disease 35 (24.6) 107 (75.4)
Platinum response 0.003
Sensitive 127 (38.6) 202 (61.4)
Resistant* 17 (21.8) 61 (78.2)
Supplementary Table S3: PARP1 and Ovarian Cancer
PARP1- N(%) PARP1+ N(%) P- value
Pathological Type <0.00001
Serous cystadenocarcinoma 84 (35.7) 151 (64.3)
Mucinous
cystadenocarcinoma
37 (78.7) 10 (21.3)
Endometrioid 40 (58.0) 29 (42.0)
Clear cell carcinoma 29 (80.6) 7 (19.4)
Mixed 3 (21.4) 11 (78.6)
FIGO Stage
0.443
I 78 (52.3) 71 (47.7)
II 29 (44.6) 36 (55.4)
III 74 (43.5) 96 (56.5)
IV 12 (48.0) 13 (52.0)
Tumour Grade
<0.00001
G1 43 (75.4) 14 (24.6)
G2 31 (46.3) 36 (53.7)




No measurable disease 138 (52.1) 127 (47.9)
Measurable disease 48 (39.7) 73 (60.3)















Serous cystadenocarcinoma 32 (14.3) 45 (20.2) 27 (12.1) 119 (53.4)
Mucinous cystadenocarcinoma 18 (45.0) 14 (35.0) 1 (2.5) 7 (17.5)
Endometrioid 21 (34.4) 14 (23.0) 6 (9.8) 20 (32.8)
Clear cell carcinoma 19 (59.4) 7 (21.9) 1 (3.1) 5 (15.6)
Mixed 1 (7.7) 2 (15.4) 3 (23.1) 7 (53.8)
FIGO Stage
0.100
I 46 (34.3) 22 (16.4) 13 (9.7) 53 (39.6)
II 11 (18.3) 14 (23.3) 7 (11.7) 28 (46.7)
III 30 (18.9) 40 (25.2) 20 (12.6) 69 (43.4)
IV 4 (16.7) 7 (29.2) 1 (4.2) 12 (50.0)
Tumour Grade
0.002
G1 22 (44.0) 15 (30.0) 1 (2.0) 12 (24.0)
G2 15 (24.2) 13 (21.0) 7 (11.3) 27 (43.5)




No measurable disease 73 (30.5) 47 (19.7) 23 (9.6) 96 (40.2)
Measurable disease 15 (13.0) 30 (26.1) 16 (13.9) 54 (47.0)
Supplementary Table S5. Multivariate analysis
PFS Sig. Exp(B) 95.0% CI for
Exp(B)
Lower Upper
Platinum Sensitivity 0.0001 13.957 9.572 20.351
XRCC1 0.016 1.503 1.078 2.096
PARP1 0.447 1.128 .827 1.539
OCSS
Platinum_Sensitivity 0.0001 6.772 4.854 9.448
XRCC1 0.170 1.258 .906 1.748
PARP1 0.023 1.421 1.051 1.922
Supplementary Table S6: BRCA2 and Ovarian Cancer
BRCA2- N (%) BRCA2+ N (%) P- value
Pathological Type 0.005
Serous cystadenocarcinoma 29 (21.3) 107 (78.7)
Mucinous
cystadenocarcinoma
11 (30.6) 25 (69.4)
Endometrioid 16 (50) 16 (50)
Clear cell carcinoma 8 (40) 12 (60)
Mixed 1 (10) 9 (90)
FIGO Stage 0.256
I 31 (31) 69 (69)
II 7 (21.2) 26 (78.8)
III 29 (30.2) 67 (69.8)
IV 0 (0) 7 (100)
Tumour Grade 0.403
G1 13 (35.1) 24 (64.9)
G2 13 (28.9) 32 (71.1)




No measurable disease 44 (27.7) 115 (72.3)
Measurable disease 20 (33.3) 40 (66.7)















Serous cystadenocarcinoma 6 (4.6) 14 (10.7) 21 (16) 90 (68.7)
Mucinous cystadenocarcinoma 4 (12.9) 10 (32.3) 5 (16.1) 12 (38.7)
Endometrioid 5 (17.2) 3 (10.3) 9 (31) 12 (41.4)
Clear cell carcinoma 5 (27.8) 2 (11.2) 3 (16.7) 8 (44.4)
Mixed 1 (11.1) 2 (22.2) 0 (0) 6 (66.7)
FIGO Stage 0.05
I 10 (11) 20 (22) 17 (18.7) 44 (48.4)
II 1 (3.2) 5 (16.1) 5 (16.1) 20 (64.5)
III 11 (12.1) 6 (6.6) 16 (17.6) 58 (63.7)
IV 0 (0) 0 (0) 0 (0) 7 (100.0)
Tumour Grade 0.098
G1 4 (12.1) 9 (27.3) 7 (21.2) 13 (39.2)
G2 3 (7) 7 (16.3) 9 (20.0) 24 (55.8)




No measurable disease 12 (8.3) 27 (18.8) 26 (18.1) 79 (54.9)
Measurable disease 9 (15.3) 2 (3.4) 10 (16.9) 38 (64.4)
Supplementary Table S8. BRCA1 and ovarian cancer
BRCA1- N(%) BRCA1+ N(%)
P- value
Pathological Type 0.048
Serous cystadenocarcinoma 62 (48.1) 67 (51.9)
Mucinous
cystadenocarcinoma
22 (66.7) 11 (33.3)
Endometrioid 22 (75.9) 7 (24.1)
Clear cell carcinoma 11 (57.9) 8 (42.1)
Mixed 6 (54.5) 5 (45.5)
FIGO Stage 0.013
I 63 (65.6) 33 (34.4)
II 10 (33.3) 20 (66.7)
III 48 (52.2) 44 (47.8)
IV 2 (40.0) 3 (60.0)
Tumour Grade 0.45
G1 19 (61.3) 12 (38.7)
G2 25 (58.1) 18 (41.9)




No measurable disease 88 (57.9) 64 (42.1)
Measurable disease 27 (48.2) 29 (51.8)
















Serous cystadenocarcinoma 16(12.8) 45(36.0) 3(2.4) 61(48.8)
Mucinous
cystadenocarcinoma
11(37.9) 9(31.0) 1(3.4) 8(27.6)
Endometrioid 6(22.2) 14(51.9) 0(0) 7(25.9)
Clear cell carcinoma 7(38.9) 4(22.2) 0(0) 7(38.9)
Mixed 0(0) 3(37.5) 1(12.5) 4(50)
FIGO Stage
0.024
I 27(30.3) 32(36.0) 1(1.1) 29(32.6)
II 3(10.3) 6(20.7) 2(6.9) 18(62.1)
III 12(13.6) 35(39.8) 3(3.4) 38(43.2)
IV 0(0) 2(40.0) 0(0) 3(60.0)
Tumour Grade
0.453G1 9(33.3) 8(29.6) 1(3.7) 9(33.3)
G2 8(19) 17(40.5) 2(4.8) 15(35.7)
G3 19(16.4) 40(34.5) 3(2.6) 54(46.6)
Measurable Disease Before
ChemoTherapy
0.042No measurable disease 34(24.3) 48(34.2) 2(1.4) 56(40.0)
Measurable disease 6(10.7) 21(37.5) 4(7.1) 25(44.6)

